abstract |
The invention relates to modulating the SIRPĪ±-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPĪ± polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia. |